September 8, 2021

Giiant Pharma Inc. appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry

MONTREAL–(BUSINESSWIRE)–Giiant Pharma Inc., a Montreal biotech company developing gut-restricted drug therapeutics at the pre-clinical stage in gastroenterology, announced the expansion of its research leadership team with the appointment of Christophe Mellon, PhD.

Christophe’s rich and varied career path led him to leadership positions in pharmaceutical, biotech, and start-up companies for more than 20 years. Recently, he had been appointed to lead a company in the material science industry.

“I am truly excited to join Giiant. I missed managing the numerous multidisciplinary fields that need to come to fruition in synchronicity to progress towards a cure. The team in place is really inspiring and the project rests on a solid foundation. I look forward to meeting each milestone in great company”, said Christophe Mellon.

“We are privileged to have Christophe joining our management team. His appointment will make a true impact on the Giiant technology platform for the development of novel patient-tailored GI therapies”, added Maxime Ranger, CEO of Giiant Pharma.

Holding a PhD from the University of Montreal, and having completed his post-doctorate at MIT, Christophe is an innovative medicinal chemist with a proven track record in entrepreneurship, as a technology inventor, investor and board member.


About Giiant Pharma

Giiant is a preclinical-stage biotech company that designs gut-restricted, tissue-specific, small molecule, drug therapeutics using its proprietary Precision Delivery technology platform which have various biological targets in gastroenterology. Its lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, with improved drug tolerability and enhanced therapeutic effect.


For more information, please contact:

Maxime Ranger, PhD MBA
CEO, giiant pharma inc.
E :
T: +1.514.825.9035
Véronique Bérubé, LLB
Head, Operations & Strategy giiant pharma inc.
T : +1.514.715.4998

September 6, 2023

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

February 24, 2023

Giiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundation

June 30, 2021

Giiant Pharma Inc. extended its Seed round with AQC Capital and CQDM to ensure reaching clinical proof-of-concept